<DOC>
	<DOC>NCT02591888</DOC>
	<brief_summary>Liposomal bupivacaine or placebo will be administered at the end of a transobturator midurethral sling to determine if there is a difference in a patient's perceived postoperative pain.</brief_summary>
	<brief_title>Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling</brief_title>
	<detailed_description>The investigators aim to evaluate the use of liposomal bupivacaine to reduce postoperative pain from placement of transobturator slings for the treatment of stress urinary incontinence.</detailed_description>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Adults &gt; 18 years of age Planning for outpatient surgical treatment of SUI with placement of a transobturator suburethral sling under general anesthesia Pregnant or nursing Allergy to bupivacaine History of drug/alcohol abuse Severe cardiovascular, hepatic, renal disease, or neurological impairmentÂ° Longacting opioid within 3 days or any opioid use within 24 hours before surgery Contraindication to: acetaminophen oxycodone nonsteroidal antiinflammatory drugs (NSAID) Administration of an investigational drug within 30 days before study Chronic pain syndromes Daily NSAID/opioid use Patients having concomitant procedures or not undergoing general anesthesia Patients who require a concomitant anterior repair or urethrocele repair will not be excluded as this requires the same dissection in the anterior vaginal wall.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>